BLT 3

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: BLT 3
Generic name: TETRACAINE
Manufacturer: CENTURA PHARMACEUTICALS INC
Product type: HUMAN OTC DRUG
SPL set ID: 401a0d22-1181-02ac-e054-00144ff88e88
SPL ID: 4839627e-93c0-0a1a-e063-6394a90a05b5
Version: 8
Effective date: 2026-01-12
Source export date: 2026-09-28
Source partition: 3
Source file: https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/fd09911bd1bc81f7f2faeb048e63855fe224e494376ae919a0035190e315c050/drug-label-0003-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:20:21

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		BLT 3	openfda.brand_name
generic name		TETRACAINE	openfda.generic_name
manufacturer name		CENTURA PHARMACEUTICALS INC	openfda.manufacturer_name
ndc	package	70372-729-01	openfda.package_ndc
ndc	product	70372-729	openfda.product_ndc
ndc11	package	70372072901	derived:openfda.package_ndc
rxcui		1858385	openfda.rxcui
spl id		4839627e-93c0-0a1a-e063-6394a90a05b5	id
spl set id		401a0d22-1181-02ac-e054-00144ff88e88	set_id
unii		0619F35CGV	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS • For external use only. • Avoid contact with eyes or mucus membranes. • Do not apply to open or damaged skin. • If condition worsens or symptoms persist for more than seven days, discontinue use and consult physician. • If pregnant or breast feeding,contact physician prior to use. • Keep out of reach of children. If swallowed, contact Poison Control Center. • Do not use if allergic to any ingredient in ointment. • Do not use in large quantities, particularly over raw surfaces or blistered areas.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.